Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Oncology Clinical Trials Market by Phase (Phase I, Phase II, Phase III, Phase IV), by Study Design (Interventional, Observational, Expanded Access) and by Cancer Type (Lung Cancer, Breast Cancer, Thyroid Cancer, Leukemia, Liver Cancer, Skin Cancer, Lymphoma, Pancreatic Cancer, Prostate Cancer, Colon Rectal Cancer, Urinary System Cancer, Other Cancer): Global Opportunity Analysis and Industry Forecast, 2023-2032

A12058

Pages: NA

Charts: NA

Tables: NA

Oncology clinical trials involve the advancement of new treatments for various cancers, and oncology is somewhat more complex than other therapeutic areas. An oncology trial not only examines the efficacy and safety of an antibiotic against infection but also tries to develop and enhance the subject's quality of life. For the management of cancer, research is progressing at a rapid pace, hence a shift has been observed for immunotherapy from chemotherapy protocols to molecularly targeted agents. Sharp growths in available clinical data, as well as a strong and growing pipeline of drug candidates, are the major trends involved in the evolution of oncology clinical trials.

COVID-19 Impact analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the oncology clinical trials market.

Top Impacting Factors

  • Increase in cases of cancer, surge in geriatric populations, rise in demand for advanced cancer treatment, supportive government initiatives, rise in need for personalized medicines, increase in cigarette smoking and obesity due to changing lifestyles increase the risk of cancer, and surge in innovation in the field of oncology are the factors that drive the growth of the oncology clinical trials market.
  • In addition, partnerships & collaborations among key players to facilitate drug development; rise in R&D activities to improve quality of drugs; increase in healthcare expenditure; availability of skilled professionals; launch of the novel developed drug in market; and technological developments are some factors, which boost the oncology clinical trials market growth.
  • Lack of awareness about clinical trials in patients, cultural & social issues related to trial participation, recruitment barriers in the clinical trial process, the deficiency of scientific knowledge, the misuse of statistics & data, the complexity of study protocol, and an adverse effect linked with the use of cancer drugs are a few reasons in the clinical trial process and are expected to hinder the oncology clinical trials market growth.
  • Contrarily, a rise in the number of pipeline drugs & huge growth potential in untapped emerging economies present new pathways in the industry.

Market Trends

New product launches to flourish the market

In June 2018, Synexus and Acurian collaboratively launched SynexusPlus, it is a solution for patient enrollment in clinical studies and is expected to raise clinical trial productivity.

In September 2019, a collaboration with Cancer Researchers was declared by IQVIA to advance the use of real-world data and extend clinical research in oncology.

In Jul 2020, a phase III clinical trial of alpelisib in combination with pertuzumab and trastuzumab was commenced by Novartis AG to evaluate the safety and efficacy to use as maintenance treatment for patients with HER2-positive advanced breast cancer.

In Mar 2021, phase II clinical trial of fixed-dose co-formulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib began by Dohme Corp. and Merck Sharp to estimate the efficacy and safety in patients with hepatocellular carcinoma (HCC).

Key Benefits of the Report

  • This study presents the analytical depiction of the oncology clinical trials industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the oncology clinical trials market share.
  • The current market is quantitatively analyzed to highlight the oncology clinical trials market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the oncology clinical trials market.
  • The report provides a detailed oncology clinical trials market analysis based on competitive intensity and how the competition will take shape in coming years

Questions answered in the Oncology Clinical Trials Report

  • Who are the leading players active in the oncology clinical trials market?
  • What is “Oncology clinical trials " Market prediction in the future?
  • Who are the leading global players in the “Oncology clinical trials “Market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the “Oncology clinical trials " Market report?                                                                                                                                                                                                                              

 Key Market Segments

  • By Phase
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • By Study Design
    • Interventional
    • Observational
    • Expanded Access
  • By Cancer Type
    • Lung Cancer
    • Breast Cancer
    • Thyroid Cancer
    • Leukemia
    • Liver Cancer
    • Skin Cancer
    • Lymphoma
    • Pancreatic Cancer
    • Prostate Cancer
    • Colon & Rectal Cancer
    • Urinary System Cancer
    • Other Cancer
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Bristol Myers Squibb company,
  • PAREXEL International Corporation,
  • Novartis AG,
  • Syneos Health
  • Merck & Co Inc.,
  • PRA Health Sciences,
  • F. Hoffmann-La Roche Ltd,
  • Novotech,
  • Pivotal,
  • Medpace

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ONCOLOGY CLINICAL TRIALS MARKET, BY PHASE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Phase

    • 4.2. Phase I

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Phase II

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Phase III

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Phase IV

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: ONCOLOGY CLINICAL TRIALS MARKET, BY STUDY DESIGN

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Study Design

    • 5.2. Interventional

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Observational

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Expanded Access

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: ONCOLOGY CLINICAL TRIALS MARKET, BY CANCER TYPE

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Cancer Type

    • 6.2. Lung Cancer

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Breast Cancer

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Thyroid Cancer

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Leukemia

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Liver Cancer

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

    • 6.7. Skin Cancer

      • 6.7.1. Key Market Trends, Growth Factors and Opportunities

      • 6.7.2. Market Size and Forecast, By Region

      • 6.7.3. Market Share Analysis, By Country

    • 6.8. Lymphoma

      • 6.8.1. Key Market Trends, Growth Factors and Opportunities

      • 6.8.2. Market Size and Forecast, By Region

      • 6.8.3. Market Share Analysis, By Country

    • 6.9. Pancreatic Cancer

      • 6.9.1. Key Market Trends, Growth Factors and Opportunities

      • 6.9.2. Market Size and Forecast, By Region

      • 6.9.3. Market Share Analysis, By Country

    • 6.10. Prostate Cancer

      • 6.10.1. Key Market Trends, Growth Factors and Opportunities

      • 6.10.2. Market Size and Forecast, By Region

      • 6.10.3. Market Share Analysis, By Country

    • 6.11. Colon And Rectal Cancer

      • 6.11.1. Key Market Trends, Growth Factors and Opportunities

      • 6.11.2. Market Size and Forecast, By Region

      • 6.11.3. Market Share Analysis, By Country

    • 6.12. Urinary System Cancer

      • 6.12.1. Key Market Trends, Growth Factors and Opportunities

      • 6.12.2. Market Size and Forecast, By Region

      • 6.12.3. Market Share Analysis, By Country

    • 6.13. Other Cancer

      • 6.13.1. Key Market Trends, Growth Factors and Opportunities

      • 6.13.2. Market Size and Forecast, By Region

      • 6.13.3. Market Share Analysis, By Country

  • CHAPTER 7: ONCOLOGY CLINICAL TRIALS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Phase

      • 7.2.3. Market Size and Forecast, By Study Design

      • 7.2.4. Market Size and Forecast, By Cancer Type

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Oncology Clinical Trials Market

        • 7.2.6.1. Market Size and Forecast, By Phase
        • 7.2.6.2. Market Size and Forecast, By Study Design
        • 7.2.6.3. Market Size and Forecast, By Cancer Type

      • 7.2.7. Canada Oncology Clinical Trials Market

        • 7.2.7.1. Market Size and Forecast, By Phase
        • 7.2.7.2. Market Size and Forecast, By Study Design
        • 7.2.7.3. Market Size and Forecast, By Cancer Type

      • 7.2.8. Mexico Oncology Clinical Trials Market

        • 7.2.8.1. Market Size and Forecast, By Phase
        • 7.2.8.2. Market Size and Forecast, By Study Design
        • 7.2.8.3. Market Size and Forecast, By Cancer Type

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Phase

      • 7.3.3. Market Size and Forecast, By Study Design

      • 7.3.4. Market Size and Forecast, By Cancer Type

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Oncology Clinical Trials Market

        • 7.3.6.1. Market Size and Forecast, By Phase
        • 7.3.6.2. Market Size and Forecast, By Study Design
        • 7.3.6.3. Market Size and Forecast, By Cancer Type

      • 7.3.7. Germany Oncology Clinical Trials Market

        • 7.3.7.1. Market Size and Forecast, By Phase
        • 7.3.7.2. Market Size and Forecast, By Study Design
        • 7.3.7.3. Market Size and Forecast, By Cancer Type

      • 7.3.8. Italy Oncology Clinical Trials Market

        • 7.3.8.1. Market Size and Forecast, By Phase
        • 7.3.8.2. Market Size and Forecast, By Study Design
        • 7.3.8.3. Market Size and Forecast, By Cancer Type

      • 7.3.9. Spain Oncology Clinical Trials Market

        • 7.3.9.1. Market Size and Forecast, By Phase
        • 7.3.9.2. Market Size and Forecast, By Study Design
        • 7.3.9.3. Market Size and Forecast, By Cancer Type

      • 7.3.10. UK Oncology Clinical Trials Market

        • 7.3.10.1. Market Size and Forecast, By Phase
        • 7.3.10.2. Market Size and Forecast, By Study Design
        • 7.3.10.3. Market Size and Forecast, By Cancer Type

      • 7.3.11. Russia Oncology Clinical Trials Market

        • 7.3.11.1. Market Size and Forecast, By Phase
        • 7.3.11.2. Market Size and Forecast, By Study Design
        • 7.3.11.3. Market Size and Forecast, By Cancer Type

      • 7.3.12. Rest Of Europe Oncology Clinical Trials Market

        • 7.3.12.1. Market Size and Forecast, By Phase
        • 7.3.12.2. Market Size and Forecast, By Study Design
        • 7.3.12.3. Market Size and Forecast, By Cancer Type

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Phase

      • 7.4.3. Market Size and Forecast, By Study Design

      • 7.4.4. Market Size and Forecast, By Cancer Type

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Oncology Clinical Trials Market

        • 7.4.6.1. Market Size and Forecast, By Phase
        • 7.4.6.2. Market Size and Forecast, By Study Design
        • 7.4.6.3. Market Size and Forecast, By Cancer Type

      • 7.4.7. Japan Oncology Clinical Trials Market

        • 7.4.7.1. Market Size and Forecast, By Phase
        • 7.4.7.2. Market Size and Forecast, By Study Design
        • 7.4.7.3. Market Size and Forecast, By Cancer Type

      • 7.4.8. India Oncology Clinical Trials Market

        • 7.4.8.1. Market Size and Forecast, By Phase
        • 7.4.8.2. Market Size and Forecast, By Study Design
        • 7.4.8.3. Market Size and Forecast, By Cancer Type

      • 7.4.9. South Korea Oncology Clinical Trials Market

        • 7.4.9.1. Market Size and Forecast, By Phase
        • 7.4.9.2. Market Size and Forecast, By Study Design
        • 7.4.9.3. Market Size and Forecast, By Cancer Type

      • 7.4.10. Australia Oncology Clinical Trials Market

        • 7.4.10.1. Market Size and Forecast, By Phase
        • 7.4.10.2. Market Size and Forecast, By Study Design
        • 7.4.10.3. Market Size and Forecast, By Cancer Type

      • 7.4.11. Thailand Oncology Clinical Trials Market

        • 7.4.11.1. Market Size and Forecast, By Phase
        • 7.4.11.2. Market Size and Forecast, By Study Design
        • 7.4.11.3. Market Size and Forecast, By Cancer Type

      • 7.4.12. Malaysia Oncology Clinical Trials Market

        • 7.4.12.1. Market Size and Forecast, By Phase
        • 7.4.12.2. Market Size and Forecast, By Study Design
        • 7.4.12.3. Market Size and Forecast, By Cancer Type

      • 7.4.13. Indonesia Oncology Clinical Trials Market

        • 7.4.13.1. Market Size and Forecast, By Phase
        • 7.4.13.2. Market Size and Forecast, By Study Design
        • 7.4.13.3. Market Size and Forecast, By Cancer Type

      • 7.4.14. Rest of Asia Pacific Oncology Clinical Trials Market

        • 7.4.14.1. Market Size and Forecast, By Phase
        • 7.4.14.2. Market Size and Forecast, By Study Design
        • 7.4.14.3. Market Size and Forecast, By Cancer Type

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Phase

      • 7.5.3. Market Size and Forecast, By Study Design

      • 7.5.4. Market Size and Forecast, By Cancer Type

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Oncology Clinical Trials Market

        • 7.5.6.1. Market Size and Forecast, By Phase
        • 7.5.6.2. Market Size and Forecast, By Study Design
        • 7.5.6.3. Market Size and Forecast, By Cancer Type

      • 7.5.7. South Africa Oncology Clinical Trials Market

        • 7.5.7.1. Market Size and Forecast, By Phase
        • 7.5.7.2. Market Size and Forecast, By Study Design
        • 7.5.7.3. Market Size and Forecast, By Cancer Type

      • 7.5.8. Saudi Arabia Oncology Clinical Trials Market

        • 7.5.8.1. Market Size and Forecast, By Phase
        • 7.5.8.2. Market Size and Forecast, By Study Design
        • 7.5.8.3. Market Size and Forecast, By Cancer Type

      • 7.5.9. UAE Oncology Clinical Trials Market

        • 7.5.9.1. Market Size and Forecast, By Phase
        • 7.5.9.2. Market Size and Forecast, By Study Design
        • 7.5.9.3. Market Size and Forecast, By Cancer Type

      • 7.5.10. Argentina Oncology Clinical Trials Market

        • 7.5.10.1. Market Size and Forecast, By Phase
        • 7.5.10.2. Market Size and Forecast, By Study Design
        • 7.5.10.3. Market Size and Forecast, By Cancer Type

      • 7.5.11. Rest of LAMEA Oncology Clinical Trials Market

        • 7.5.11.1. Market Size and Forecast, By Phase
        • 7.5.11.2. Market Size and Forecast, By Study Design
        • 7.5.11.3. Market Size and Forecast, By Cancer Type

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. PAREXEL International Corporation,

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. PRA Health Sciences,

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Syneos Health

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Medpace

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Novotech,

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Pivotal,

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Novartis AG,

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Merck And Co Inc.,

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Bristol Myers Squibb Company,

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. F. Hoffmann-La Roche Ltd,

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR PHASE I, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR PHASE II, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR PHASE III, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR PHASE IV, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR INTERVENTIONAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR OBSERVATIONAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR EXPANDED ACCESS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR LUNG CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR BREAST CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR THYROID CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR LEUKEMIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR LIVER CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR SKIN CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR LYMPHOMA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR PANCREATIC CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR PROSTATE CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR COLON AND RECTAL CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR URINARY SYSTEM CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET FOR OTHER CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 24. NORTH AMERICA ONCOLOGY CLINICAL TRIALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 25. NORTH AMERICA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 26. NORTH AMERICA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 27. NORTH AMERICA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 28. U.S. ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 29. U.S. ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 30. U.S. ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 31. CANADA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 32. CANADA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 33. CANADA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 34. MEXICO ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 35. MEXICO ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 36. MEXICO ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 37. EUROPE ONCOLOGY CLINICAL TRIALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 38. EUROPE ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 39. EUROPE ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 40. EUROPE ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 41. FRANCE ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 42. FRANCE ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 43. FRANCE ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 44. GERMANY ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 45. GERMANY ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 46. GERMANY ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 47. ITALY ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 48. ITALY ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 49. ITALY ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 50. SPAIN ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 51. SPAIN ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 52. SPAIN ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 53. UK ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 54. UK ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 55. UK ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 56. RUSSIA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 57. RUSSIA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 58. RUSSIA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 59. REST OF EUROPE ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 60. REST OF EUROPE ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 61. REST OF EUROPE ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 62. ASIA-PACIFIC ONCOLOGY CLINICAL TRIALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 63. ASIA-PACIFIC ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 64. ASIA-PACIFIC ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 65. ASIA-PACIFIC ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 66. CHINA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 67. CHINA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 68. CHINA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 69. JAPAN ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 70. JAPAN ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 71. JAPAN ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 72. INDIA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 73. INDIA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 74. INDIA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 75. SOUTH KOREA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 76. SOUTH KOREA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 77. SOUTH KOREA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 78. AUSTRALIA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 79. AUSTRALIA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 80. AUSTRALIA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 81. THAILAND ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 82. THAILAND ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 83. THAILAND ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 84. MALAYSIA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 85. MALAYSIA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 86. MALAYSIA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 87. INDONESIA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 88. INDONESIA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 89. INDONESIA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 90. REST OF ASIA PACIFIC ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 91. REST OF ASIA PACIFIC ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 92. REST OF ASIA PACIFIC ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 93. LAMEA ONCOLOGY CLINICAL TRIALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 94. LAMEA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 95. LAMEA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 96. LAMEA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 97. BRAZIL ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 98. BRAZIL ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 99. BRAZIL ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 100. SOUTH AFRICA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 101. SOUTH AFRICA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 102. SOUTH AFRICA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 103. SAUDI ARABIA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 104. SAUDI ARABIA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 105. SAUDI ARABIA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 106. UAE ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 107. UAE ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 108. UAE ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 109. ARGENTINA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 110. ARGENTINA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 111. ARGENTINA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 112. REST OF LAMEA ONCOLOGY CLINICAL TRIALS, BY PHASE, 2025-2033 ($MILLION)
  • TABLE 113. REST OF LAMEA ONCOLOGY CLINICAL TRIALS, BY STUDY DESIGN, 2025-2033 ($MILLION)
  • TABLE 114. REST OF LAMEA ONCOLOGY CLINICAL TRIALS, BY CANCER TYPE, 2025-2033 ($MILLION)
  • TABLE 115. PAREXEL INTERNATIONAL CORPORATION,: KEY EXECUTIVES
  • TABLE 116. PAREXEL INTERNATIONAL CORPORATION,: COMPANY SNAPSHOT
  • TABLE 117. PAREXEL INTERNATIONAL CORPORATION,: OPERATING SEGMENTS
  • TABLE 118. PAREXEL INTERNATIONAL CORPORATION,: PRODUCT PORTFOLIO
  • TABLE 119. PAREXEL INTERNATIONAL CORPORATION,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. PRA HEALTH SCIENCES,: KEY EXECUTIVES
  • TABLE 121. PRA HEALTH SCIENCES,: COMPANY SNAPSHOT
  • TABLE 122. PRA HEALTH SCIENCES,: OPERATING SEGMENTS
  • TABLE 123. PRA HEALTH SCIENCES,: PRODUCT PORTFOLIO
  • TABLE 124. PRA HEALTH SCIENCES,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. SYNEOS HEALTH: KEY EXECUTIVES
  • TABLE 126. SYNEOS HEALTH: COMPANY SNAPSHOT
  • TABLE 127. SYNEOS HEALTH: OPERATING SEGMENTS
  • TABLE 128. SYNEOS HEALTH: PRODUCT PORTFOLIO
  • TABLE 129. SYNEOS HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. MEDPACE: KEY EXECUTIVES
  • TABLE 131. MEDPACE: COMPANY SNAPSHOT
  • TABLE 132. MEDPACE: OPERATING SEGMENTS
  • TABLE 133. MEDPACE: PRODUCT PORTFOLIO
  • TABLE 134. MEDPACE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. NOVOTECH,: KEY EXECUTIVES
  • TABLE 136. NOVOTECH,: COMPANY SNAPSHOT
  • TABLE 137. NOVOTECH,: OPERATING SEGMENTS
  • TABLE 138. NOVOTECH,: PRODUCT PORTFOLIO
  • TABLE 139. NOVOTECH,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. PIVOTAL,: KEY EXECUTIVES
  • TABLE 141. PIVOTAL,: COMPANY SNAPSHOT
  • TABLE 142. PIVOTAL,: OPERATING SEGMENTS
  • TABLE 143. PIVOTAL,: PRODUCT PORTFOLIO
  • TABLE 144. PIVOTAL,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. NOVARTIS AG,: KEY EXECUTIVES
  • TABLE 146. NOVARTIS AG,: COMPANY SNAPSHOT
  • TABLE 147. NOVARTIS AG,: OPERATING SEGMENTS
  • TABLE 148. NOVARTIS AG,: PRODUCT PORTFOLIO
  • TABLE 149. NOVARTIS AG,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. MERCK AND CO INC.,: KEY EXECUTIVES
  • TABLE 151. MERCK AND CO INC.,: COMPANY SNAPSHOT
  • TABLE 152. MERCK AND CO INC.,: OPERATING SEGMENTS
  • TABLE 153. MERCK AND CO INC.,: PRODUCT PORTFOLIO
  • TABLE 154. MERCK AND CO INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 155. BRISTOL MYERS SQUIBB COMPANY,: KEY EXECUTIVES
  • TABLE 156. BRISTOL MYERS SQUIBB COMPANY,: COMPANY SNAPSHOT
  • TABLE 157. BRISTOL MYERS SQUIBB COMPANY,: OPERATING SEGMENTS
  • TABLE 158. BRISTOL MYERS SQUIBB COMPANY,: PRODUCT PORTFOLIO
  • TABLE 159. BRISTOL MYERS SQUIBB COMPANY,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 160. F. HOFFMANN-LA ROCHE LTD,: KEY EXECUTIVES
  • TABLE 161. F. HOFFMANN-LA ROCHE LTD,: COMPANY SNAPSHOT
  • TABLE 162. F. HOFFMANN-LA ROCHE LTD,: OPERATING SEGMENTS
  • TABLE 163. F. HOFFMANN-LA ROCHE LTD,: PRODUCT PORTFOLIO
  • TABLE 164. F. HOFFMANN-LA ROCHE LTD,: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET
  • FIGURE 3. SEGMENTATION ONCOLOGY CLINICAL TRIALS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ONCOLOGY CLINICAL TRIALS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALONCOLOGY CLINICAL TRIALS MARKET
  • FIGURE 11. ONCOLOGY CLINICAL TRIALS MARKET SEGMENTATION, BY BY PHASE
  • FIGURE 12. ONCOLOGY CLINICAL TRIALS MARKET FOR PHASE I, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ONCOLOGY CLINICAL TRIALS MARKET FOR PHASE II, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ONCOLOGY CLINICAL TRIALS MARKET FOR PHASE III, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. ONCOLOGY CLINICAL TRIALS MARKET FOR PHASE IV, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. ONCOLOGY CLINICAL TRIALS MARKET SEGMENTATION, BY BY STUDY DESIGN
  • FIGURE 17. ONCOLOGY CLINICAL TRIALS MARKET FOR INTERVENTIONAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. ONCOLOGY CLINICAL TRIALS MARKET FOR OBSERVATIONAL, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. ONCOLOGY CLINICAL TRIALS MARKET FOR EXPANDED ACCESS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. ONCOLOGY CLINICAL TRIALS MARKET SEGMENTATION, BY BY CANCER TYPE
  • FIGURE 21. ONCOLOGY CLINICAL TRIALS MARKET FOR LUNG CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. ONCOLOGY CLINICAL TRIALS MARKET FOR BREAST CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. ONCOLOGY CLINICAL TRIALS MARKET FOR THYROID CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. ONCOLOGY CLINICAL TRIALS MARKET FOR LEUKEMIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. ONCOLOGY CLINICAL TRIALS MARKET FOR LIVER CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. ONCOLOGY CLINICAL TRIALS MARKET FOR SKIN CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. ONCOLOGY CLINICAL TRIALS MARKET FOR LYMPHOMA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. ONCOLOGY CLINICAL TRIALS MARKET FOR PANCREATIC CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 29. ONCOLOGY CLINICAL TRIALS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 30. ONCOLOGY CLINICAL TRIALS MARKET FOR COLON AND RECTAL CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 31. ONCOLOGY CLINICAL TRIALS MARKET FOR URINARY SYSTEM CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 32. ONCOLOGY CLINICAL TRIALS MARKET FOR OTHER CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 33. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 34. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 35. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 36. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 37. COMPETITIVE DASHBOARD
  • FIGURE 38. COMPETITIVE HEATMAP: ONCOLOGY CLINICAL TRIALS MARKET
  • FIGURE 39. TOP PLAYER POSITIONING, 2024
  • FIGURE 40. PAREXEL INTERNATIONAL CORPORATION,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. PAREXEL INTERNATIONAL CORPORATION,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. PAREXEL INTERNATIONAL CORPORATION,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. PRA HEALTH SCIENCES,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. PRA HEALTH SCIENCES,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. PRA HEALTH SCIENCES,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. SYNEOS HEALTH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. SYNEOS HEALTH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. SYNEOS HEALTH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. MEDPACE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. MEDPACE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. MEDPACE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. NOVOTECH,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. NOVOTECH,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. NOVOTECH,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. PIVOTAL,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. PIVOTAL,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. PIVOTAL,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 58. NOVARTIS AG,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 59. NOVARTIS AG,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 60. NOVARTIS AG,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 61. MERCK AND CO INC.,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 62. MERCK AND CO INC.,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 63. MERCK AND CO INC.,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 64. BRISTOL MYERS SQUIBB COMPANY,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 65. BRISTOL MYERS SQUIBB COMPANY,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 66. BRISTOL MYERS SQUIBB COMPANY,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 67. F. HOFFMANN-LA ROCHE LTD,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 68. F. HOFFMANN-LA ROCHE LTD,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 69. F. HOFFMANN-LA ROCHE LTD,: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Oncology Clinical Trials Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved